A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Inclusion Criteria:

- Male and female patients age at least 18 years of age, or age of consent in the
region.

- Newly diagnosed Stage IIIB or IV non-small cell lung cancer (according to Revised
International System for Staging Lung Cancer criteria of 2010) or recurrent non-small
cell lung cancer (NSCLC).

- Histologically or cytologically confirmed diagnosis of predominately non-squamous
NSCLC.

- Be eligible to receive study treatment of bevacizumab, paclitaxel, and carboplatin
based on local standard of care, for the treatment of advanced or metastatic
non-squamous NSCLC.

Exclusion Criteria:

- Small cell lung cancer (SCLC) or combination SCLC and NSCLC. Squamous-cell tumors and
mixed adenosquamous carcinomas of predominantly squamous nature.

- Evidence of a tumor that compresses or invades major blood vessels or tumor cavitation
that is likely to bleed.

- Known sensitizing EGFR mutations (for example, deletion 19 or L858R) or EML4-ALK
translocation positive mutations.

- Prior systemic therapy for NSCLC; prior neoadjuvant or adjuvant therapy is allowed if
surgical resection for primary disease was performed.